BIOGEN INC. - COMMON STOCK

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

03 11 2025 04:30:00 提供 Nasdaq GlobeNewswire

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease

26 10 2025 16:30:00 提供 Nasdaq GlobeNewswire

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

24 10 2025 04:30:44 提供 Nasdaq GlobeNewswire

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

22 10 2025 04:30:00 提供 Nasdaq GlobeNewswire

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

13 10 2025 16:30:00 提供 Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

09 10 2025 13:30:00 提供 Nasdaq GlobeNewswire

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

06 10 2025 13:30:00 提供 Nasdaq GlobeNewswire

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

28 9 2025 16:30:00 提供 Nasdaq GlobeNewswire

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

24 9 2025 04:30:00 提供 Nasdaq GlobeNewswire

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

23 9 2025 13:30:00 提供 Nasdaq GlobeNewswire

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

18 9 2025 04:40:01 提供 Nasdaq GlobeNewswire

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

17 9 2025 13:30:05 提供 Nasdaq GlobeNewswire

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

02 9 2025 16:30:33 提供 Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

02 9 2025 04:00:01 提供 Nasdaq GlobeNewswire

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

29 8 2025 14:00:00 提供 Nasdaq GlobeNewswire

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

25 8 2025 00:00:00 提供 Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

11 8 2025 04:00:00 提供 Nasdaq GlobeNewswire

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

30 7 2025 08:00:00 提供 Nasdaq GlobeNewswire

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

25 7 2025 04:20:26 提供 Nasdaq GlobeNewswire

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

21 7 2025 16:30:00 提供 Nasdaq GlobeNewswire